TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2120639
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg h‐1 intra‐arterial rt‐PA
Study: 2120639
Drug: 5000 units
Normalized name: A-25, 25000 units oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 units h‐1 Sk and 250 units h‐1 heparin intra‐arterially
Study: 224083
Drug: Stannous fluoride
Normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stannous fluoride dentifrice in a silica gel base
Study: 29967948
Drug: Deep neuromuscular
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep neuromuscular blockade (NMB) with 4 mg/kg sugammadex at post-tetanic count (PTC) of 2
Study: 29967948
Drug: Moderate neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate neuromuscular blockade (NMB) with 2 mg/kg sugammadex at a train-of-four (TOF) count of 1 or 2
Study: 28854592
Drug: Weight reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight reduction intervention followed by IVF treatment; 12 weeks of low calorie liquid formula diet (LCD) of 880 kcal/day followed by weight stabilization for 2-5 weeks.
Study: 28854592
Drug: IVF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF treatment only.
Study: 11480656
Drug: Cognitive-behavioral insomnia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral insomnia therapy (CBT)
Study: 9926274
Drug: salbutamol 8
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol 8 mg
Study: 1687425
Drug: pindolol 10
Normalized name: pindolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol 10 mg
Study: 3058043
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin 2 (IL2) administered intravenously at doses of 1 x 10(4), 3.3 ‐ 5 x 10(4), 1 x 10(5), 3.3‐5 x 10(5), 1 x 10(6) and 3.3 x 10(6) U/day
Study: 3058043
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin 2 (IL2) administered subcutaneously at a dose of 1 x 10(6) U/day for 5 days
Study: 25403646
Drug: LCZ696 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 (400 mg daily)
Study: 19061537
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS), 110 microg/day, once daily
Study: 19061537
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray (FPNS), 200 microg/day, twice daily
Study: 16505427
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 40,000 U subcutaneously weekly (40K arm)
Study: 15284376
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d of elemental iron alone
Study: 15284376
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d of elemental iron in combination with multimicronutrients
Study: 11052409
Drug: Nortriptyline (NT)
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nortriptyline (NT) at a mean dose of 80 mg (1.8 mg/kg/day) during the open phase
Study: 11052409
Drug: Nortriptyline (NT)
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nortriptyline (NT) during the discontinuation phase
Study: 11052409
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during the discontinuation phase
Study: 9333770
Drug: TSH-receptor antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSH-receptor antibodies (TRAb) detection
Study: 9333770
Drug: Thyroperoxidase antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroperoxidase antibodies (TPO‐Ab) estimation
Study: 9333770
Drug: Thyrostatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrostatic treatment of Graves' disease
Study: 8039151
Drug: CEF with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF with G-CSF
Study: 20707790
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 60 mg extended release (ER)
Study: 16549856
Drug: PSA threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA threshold below 4.0 ng/mL
Study: 8691967
Drug: d-sotalol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-sotalol (100 mg increased to 200 mg twice daily, if tolerated)
Study: 1755948
Drug: Pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (100 mg)
Study: 1755948
Drug: Chlorprothixene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorprothixene (30 mg)
Study: 1755948
Drug: Ketotifen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (3 mg)
Study: 27824277
Drug: Lactobacillus brevis
Normalized name: Lactobacillus brevis
DrugBank: Lactobacillus brevis (DB18532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus brevis DSM17250 extract (ointment formulation)
Study: 24532827
Drug: Multitiered intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multitiered intervention with enhanced core reading instruction and additional 30-min daily small group intervention
Study: 12026536
Drug: SIT (Specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT (Specific Immunotherapy) with mixed grass pollen allergens (Allergovit, Pollinex)
Study: 12026536
Drug: SIT (Specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT (Specific Immunotherapy) with mixed grass pollen allergens
Study: 9824782
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 0.05 mg/kg (3.5 mg for 70-kg body weight)
Study: 31155392
Drug: Hydrocortisone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (0.5 mg/kg/6 hours)
Study: 9222076
Drug: Trovafloxacin 100
Normalized name: trovafloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 100 mg tablets (fasted)
Study: 9222076
Drug: Alatrofloxacin (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alatrofloxacin (IV infusion)
Study: 9222076
Drug: Trovafloxacin 100
Normalized name: trovafloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 100 mg tablets (after standard breakfast)
Study: 9222076
Drug: Trovafloxacin 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 300 mg oral aqueous suspension (fasted)
Study: 8107542
Drug: Rehydration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehydration with 1.5 l of water over 2 h after 24 h of dehydration
Study: 3105747
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein diet (median 92 g/day)
Study: 3105747
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (47 g/day)
Study: 24472873
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy targeting normal‐for‐age fasting blood glucose concentrations
Study: 24472873
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion only to prevent excessive hyperglycemia
Study: 12234955
Drug: Paxil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paxil (20 mg/d) for 6 weeks
Study: 9637806
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus Clomiphene
Study: 21063110
Drug: Syzygium cumini
Normalized name: SYZYGIUM CUMINI SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syzygium cumini aqueous leaves extract (ASc) at 100 μg/mL
Study: 21063110
Drug: Syzygium cumini
Normalized name: SYZYGIUM CUMINI SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syzygium cumini aqueous leaves extract (ASc) at 200 μg/mL
Study: 17409123
Drug: Bed Rest
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bed Rest plus Essential Amino Acid and Carbohydrate Supplement (BRAA)
Study: 2570286
Drug: UK 69
Normalized name: UK-390957
DrugBank: UK-390957 (DB11719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK 69 578 (a competitive inhibitor of endopeptidase 24.11)
Study: 1096122
Drug: Nystatin cream
Normalized name: Nystatin Cream
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nystatin cream
Study: 326494
Drug: Nystatin/triamcinolone acetonide
Normalized name: nystatin/triamcinolone acetonide TOPICAL CREAM (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin/triamcinolone acetonide combination cream
Study: 23474890
Drug: Codeine/Paracetamol 20/400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine/Paracetamol 20/400 mg
Study: 23474890
Drug: Codeine/Paracetamol 40/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine/Paracetamol 40/800 mg
Study: 23474890
Drug: Codeine/Paracetamol 60/1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine/Paracetamol 60/1200 mg
Study: 15067655
Drug: Bupivacaine 20
Normalized name: BUPIVACAINE 200MG/MELOXICAM 6MG/VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 20 mL 0.5% (100 mg)
Study: 3290233
Drug: Antimicrobial agent
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial agent
Study: 21440263
Drug: Conventional preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional preparation of the other leg
Study: 20038402
Drug: Peri-interventional antibiotic
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-interventional antibiotic treatment with cefuroxime, 20 mg/kg three times per day for 24 hours
Study: 20038402
Drug: Prolonged antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged antibiotic treatment with cefuroxime, 20 mg/kg three times per day for 7 days
Study: 15329902
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin at 50 mg/m2 every 4 weeks for 6 cycles (Group B)
Study: 15329902
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin at 25 mg/m2 every 2 weeks for 12 cycles (Group A)
Study: 15329902
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (50 mg/m2 every 4 weeks for 6 cycles)
Study: 15329902
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (25 mg/m2 every 2 weeks for 12 cycles)
Study: 11061509
Drug: Arginine (ARG;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine (ARG; 0.5 g/kg, iv, from 0-30 min)
Study: 2868337
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (SK) in addition to usual treatment
Study: 2868337
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual treatment only)
Study: 24999127
Drug: Surgical tracheostomy
Normalized name: TRACHEOSTOMY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical tracheostomy (ST) using Charles G Durbin technique
Study: 22874424
Drug: High-carbohydrate beverage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate beverage (3.4 g glucose + 3.1 g fructose per deciliter)
Study: 22874424
Drug: Control beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control beverage (0.0 g glucose + 0.0 g fructose per deciliter)
Study: 22874424
Drug: Low-carbohydrate beverage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate beverage (1.7 g glucose + 1.6 g fructose per deciliter)
Study: 15879435
Drug: Albuterol (beta-agonist)
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (beta-agonist) with glucocorticoid
Study: 14673758
Drug: Granulocyte-macrophage colony-stimulating
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) 250 microg administered subcutaneously 3 times/week for 16 weeks
Study: 8883267
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin (5000 U bolus followed by 1000 U/h infusion)
Study: 8883267
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (12,500 U every 12 h, started 4 h after streptokinase)
Study: 6091079
Drug: Antacid preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid preparations
Study: 30183260
Drug: Hydrogel formulation
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel formulation of dapivirine
Study: 30183260
Drug: Film-based formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-based formulation of dapivirine
Study: 20416132
Drug: Quercetin 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 150 mg per day for 6 weeks
Study: 18092452
Drug: LANAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LANAP treatment with Nd:YAG laser
Study: 18092452
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (scaling and root planing without laser)
Study: 12632439
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (triamcinolone hexacetonide 40 mg) + supervised physiotherapy
Study: 12632439
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection alone
Study: 12632439
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection + supervised physiotherapy
Study: 12632439
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection alone (placebo group)
Study: 8719534
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic cream (EMLA)
Study: 1827575
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 1,200 mg/day (Group A: 28 patients)
Study: 1827575
Drug: Cyclophosphamide (CPA)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CPA) 100 mg/day in combination with MPA (Group B: 20 patients)
Study: 1827575
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 1,200 mg/day (Group A)
Study: 1827575
Drug: Cyclophosphamide (CPA)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CPA) 100 mg/day in combination with MPA (Group B)
Study: 7387963
Drug: Xenon arc
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xenon arc photocoagulation treatment
Study: 28096223
Drug: Basal plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal plus prandial insulin therapy
Study: 21991732
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg) + Bupivacaine (5 mg/ml)
Study: 21991732
Drug: Meperidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (1 mg/kg) + Bupivacaine (5 mg/ml)
Study: 19438906
Drug: Pegvisomant monotherapy
Normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegvisomant monotherapy (PM) - 10 mg once daily initially, adjusted in 5-mg increments every 8 weeks based on IGF‐I levels
Study: 19438906
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of pegvisomant and long-acting octreotide (P-LAR) - LAR dosing remained fixed
Study: 17276147
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily (OD) tobramycin
Study: 17276147
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily (TD) tobramycin
Study: 8751024
Drug: Jet-injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet-injection of recombinant human growth hormone (rhGH)
Study: 8751024
Drug: Needle-injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-injection of recombinant human growth hormone (rhGH)
Study: 8751024
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (jet-injection and needle-injection)
Study: 2208022
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of chemotherapy
Study: 31403507
Drug: Inhaled nitrous
Normalized name: nitrous oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitrous oxide (N2O)
Study: 28272716
Drug: NBCA medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBCA medical adhesive for patch fixation
Study: 28272716
Drug: Without patch
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Without patch fixation (control group)
Study: 21353720
Drug: G-CSF administered
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administered concurrently with radiotherapy (RT)
Study: 19210693
Drug: darunavir/RTV 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/RTV 800/100 mg qd
Study: 19210693
Drug: atazanavir/RTV 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: atazanavir/RTV 300/100 mg qd
Study: 9548039
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with intravenous midazolam (5 mg for those under 65 years or 3 mg for those aged 65 or more)
Study: 23210197
Drug: Chlorhexidine (CHX)
Normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (CHX) gel
Study: 22113220
Drug: Navigated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navigated treatment (Group B)
Study: 19772268
Drug: Early laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early laser photocoagulation treatment
Study: 12174103
Drug: Cipamfylline (0.15%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cipamfylline (0.15%) cream
Study: 12174103
Drug: Hydrocortisone 17-butyrate
Normalized name: Cortisol 17-butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone 17-butyrate (0.1%) cream
Study: 7648380
Drug: Uni-Dur 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uni-Dur 800 mg once-daily
Study: 7648380
Drug: Uni-Dur 400
Normalized name: Uni-Dur 400 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uni-Dur 400 mg twice-daily
Study: 7648380
Drug: Uniphyl 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphyl 800 mg once-daily
Study: 2704503
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17 beta‐estradiol + norethisterone acetate 1 mg
Study: 2704503
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17 beta‐estradiol + megestrol acetate 5 mg
Study: 2704503
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17 beta‐estradiol + norethisterone acetate 0.5 mg
Study: 2704503
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17 beta‐estradiol + megestrol acetate 2.5 mg
Study: 23258626
Drug: Testosterone patch
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch for 36 months
Study: 25100359
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch for 36 months
Study: 19549428
Drug: Loratadine/montelukast (L/M;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine/montelukast (L/M; 10 mg/10 mg)
Study: 17258304
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICSs) for 48 months or more
Study: 17258304
Drug: Nonusers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonusers of inhaled corticosteroids (ICSs)
Study: 17258304
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICSs) for 4 years or more in subjects with high total IgE (>100 kU/L)
Study: 17258304
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICSs) in subjects with lower total IgE
Study: 15606733
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream applied 5 times/week for 4 weeks
Study: 15606733
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream applied 5 times/week for 6 weeks
Study: 23712737
Drug: levamisole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: levamisole (5 mg/rat/day)
Study: 22117578
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment and care (Control group)
Study: 19326108
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CaCO(3), n = 8), 500 mg bid
Study: 17728427
Drug: Aripiprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (10 mg, 15 mg, 20 mg, or 30 mg)
Study: 15054430
Drug: Two portions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two portions (300 g) of fruits and vegetables daily